| Literature DB >> 25252297 |
Nermin Bayar1, Erdal Kurtoğlu, Şakir Arslan, Zehra Erkal, Serkan Çay, Göksel Çağırcı, Burak Deveci, Selçuk Küçükseymen.
Abstract
OBJECTIVE: Beta-thalassemia major (TM) is a genetic hemoglobin disorder causing chronic hemolytic anemia. Since cardiac insufficiency and arrhythmias are the primary causes of mortality in such patients, monitoring of cardiac iron load is important in management of the disorder. The purpose of this study was to investigate the importance of fragmented QRS (fQRS) and its relation to the cardiac T2* value for the evaluation of cardiac iron load in TM patients.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25252297 PMCID: PMC5336998 DOI: 10.5152/akd.2014.5188
Source DB: PubMed Journal: Anatol J Cardiol ISSN: 2149-2263 Impact factor: 1.596
Demographic characteristics with and without cardiac involvement
| Variables | Cardiac involvement (+) (n=43) | Cardiac involvement (-) (n=60) | |
|---|---|---|---|
| Age, years | 22 (20-27) | 21 (18-25) | 0.299 |
| Male gender, n (%) | 19 (44%) | 27 (45%) | 0.935 |
| Trigliseride, mg/dL | 165±93 | 122±46 | 0.003 |
| LDL, mg/dL | 68±37 | 54±24 | 0.029 |
| HDL, mg/dL | 28±11 | 30±10 | 0.384 |
| Total cholesterol, mg/dL | 128±47 | 110±29 | 0.019 |
| Hemoglobin, g/dL | 8 (8-9) | 8 (8-9) | 0.634 |
| WBC, 103/mm3 | 10 (6-25) | 8 (6-17) | 0.278 |
| PLT, 103/mm3 | 418±218 | 405±224 | 0.775 |
| EDD, mm | 45±4 | 47±4 | 0.020 |
| ESD, mm | 28±4 | 30±4 | 0.050 |
| LVEF, % | 60 (58-65) | 60 (60-65) | 0.214 |
| fQRS present | 37 (86%) | 13 (22%) | <0.001 |
| T2* value | 13±3 | 33±10 | <0.001 |
Which show a normal distribution mean±SD, not show a normal distribution median 25. and 75. percentile EDD - left ventricular end-diastolic diamater; ESD - left ventricular end-systolic diamater; LVEF - left ventricular ejection fraction; WBC - white blood cell
Figure 1Patients with cardiac involvement, have been seen more frequently in the presence of fQRS
In univariate regression analysis, were investigated which is associated with cardiac involvement cases and fQRS was significantly correlated with the presence of cardiac involvement
| Variables | OR | 95% CI | |
|---|---|---|---|
| fQRS present | 22.3 | 7.7-64.3 | <0.001 |
| Deferiprone | 1.85 | 0.82-4.18 | 0.141 |
| Deferoxamine | 2.73 | 1.21-6.14 | 0.015 |
| Deferiprone+Deferoxamine | 2.46 | 0.94-6.43 | 0.067 |
| Deferasirox | 0.38 | 0.17-0.87 | 0.021 |
Iron chelates used in association with cardiac involvement were evaluated
| Variables | Cardiac involvement (+) | Cardiac involvement (-) | |
|---|---|---|---|
| Deferiprone | 19 (44%) | 18 (30%) | 0.139 |
| Deferoxamine | 24 (56%) | 19 (32%) | 0.012 |
| Deferiprone+Deferoxamine | 13 (30%) | 9 (15%) | 0.054 |
| Deferasirox | 13 (30%) | 32 (53%) | 0.016 |
Iron chelates used in association with the presence of fQRS, were evaluated
| Variables | fQRS (+) (n=50) | fQRS (-) (n=53) | |
|---|---|---|---|
| Deferiprone | 22 (44%) | 15 (28%) | 0.097 |
| Deferoxamine | 30 (60%) | 13 (25%) | <0.001 |
| Deferiprone+Deferoxamine | 14 (28%) | 8 (15%) | 0.110 |
| Deferasirox | 12 (24%) | 33 (62%) | <0.001 |
In multivariate regression analysis for fQRS, cardiac iron overload was significantly correlated with the presence fQRS
| Variables | OR | 95% CI | |
|---|---|---|---|
| Age (For every 1 year) | 1.064 | 0.993-1.141 | 0.079 |
| Deferiprone | 0.320 | 0.059-1.750 | 0.189 |
| Deferoxamine | 0.903 | 0.157-5.190 | 0.909 |
| Deferasirox | 0.087 | 0.008-0.941 | 0.044 |
| Cardiac involvement | 27.488 | 8.170-92.481 | <0.001 |